Literature DB >> 23652790

Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Peter K Wong1, Gelsomina L Borromeo, John D Wark.   

Abstract

Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for osteoporosis and Paget's disease. These drugs reduce fracture risk and probably mortality in patients with osteoporosis. However, they have a long in vivo half-life following cessation and may be associated with delayed dental healing and even the devastating complication of osteonecrosis of the jaw (ONJ). Extensive media attention highlighting this issue has caused much concern among patients and healthcare professionals. This paper seeks to provide treating clinicians with a balanced multi-disciplinary review of the available evidence pertaining to this issue and practical advice regarding prevention and management of ONJ.

Entities:  

Mesh：

Year:  2013        PMID： 23652790     DOI： 10.1007/s00296-013-2771-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  121 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

2.  Bisphosphonates and osteonecrosis of the jaw.

Authors:  Patrick M Purcell; Ian W Boyd
Journal:  Med J Aust       Date:  2005-04-18       Impact factor: 7.738

Review 3.  Osteonecrosis of the jaw: who gets it, and why?

Authors:  Ian R Reid
Journal:  Bone       Date:  2008-10-07       Impact factor: 4.398

4.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Avvisati; Giordano Dicuonzo; Fabrizio Battistoni; Michele Gavasci; Alfredo Salerno; Vincenzo Denaro; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Meta-analysis: excess mortality after hip fracture among older women and men.

Authors:  Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

6.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Authors:  Tony Mavrokokki; Andrew Cheng; Brien Stein; Alastair Goss
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

7.  Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?

Authors:  Hani Mawardi; Nathaniel Treister; Paul Richardson; Kenneth Anderson; Nikhil Munshi; Robert A Faiella; Sook-Bin Woo
Journal:  J Oral Maxillofac Surg       Date:  2009-03       Impact factor: 1.895

8.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 9.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Authors:  Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki
Journal:  Am J Med       Date:  2012-11-20       Impact factor: 4.965

10.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Authors:  C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976
View more
  3 in total

1.  Bisphosphonate-Related Osteonecrosis of the Jaws and Its Array of Manifestations.

Authors:  Gustavo Davi Rabelo; José Narciso Rosa Assunção; Pascale Chavassieux; Haroldo Arid Soares; Fabio Abreu Alves; Celso Augusto Lemos
Journal:  J Maxillofac Oral Surg       Date:  2014-10-15

2.  Summary of the various treatments for osteonecrosis of the femoral head by mechanism: A review.

Authors:  Cheng Wang; Jiang Peng; Shibi Lu
Journal:  Exp Ther Med       Date:  2014-06-26       Impact factor: 2.447

3.  Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate.

Authors:  Ryuta Arai; Daisuke Takahashi; Masahiro Inoue; Tohru Irie; Tsuyoshi Asano; Takuya Konno; Mohamad Alaa Terkawi; Tomohiro Onodera; Eiji Kondo; Norimasa Iwasaki
Journal:  BMC Musculoskelet Disord       Date:  2017-01-19       Impact factor: 2.362
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.